Infliximab is a chimeric monoclonal antibody that binds to tumor necrosis factor-alpha (TNF-α) which is major cytokine playing pivotal role in inflammatory diseases. Efficacy and safety of infliximab was studied in numerous inflammatory skin diseases where TNF-α is involved in pathogenesis especially in psoriasis and psoriatic arthritis. This review summarizes the current data revealing the efficacy and safety of infliximab in treating various dermatoses beyond its approved indications. Results of clinical trials and case reports suggest that infliximab is a promising agent in treating inflammatory cutaneous dermatoses where conventional therapies fail to respond or have limited effect due to potential side effects.
Keywords: Infliximab, tumor necrosis factor-α, psoriasis, cutaneous dermatoses
Rights & PermissionsPrintExport